Clinical Trial Update: PS-341 in Treating Patients With Hematologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of PS-341 (bortezomib) in hematologic cancers; the study has completed and includes leukemia, lymphoma, multiple myeloma and related plasma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Plasma Cell Neoplasm

Drugs mentioned

• PS-341 (bortezomib) (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED